| Project/Area Number |
26861119
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Tokyo Women's Medical University (2015-2016)
Chiba University (2014) |
|---|
Principal Investigator |
Kamata Toshiko 東京女子医科大学, 医学部, 助教 (60586692)
|
|---|
| Research Collaborator |
MOTOHASHI Shinichiro 千葉大学, 大学院医学研究院・免疫細胞医学, 教授 (60345022)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | NKT細胞治療 / 抗PDL1抗体 / 癌免疫治療 / NKT細胞 / PD-1 |
|---|
| Outline of Final Research Achievements |
There are few researches on the function of PD-1/PDL1 in human NKT cells. In our research, we found that PD-1 was upregulated in activated NKT cells and NKT cells derived from lung cancer patients.
Cytokine secretion and anti-tumor functions of NKT cells improved when the ligand for PD-1 (PDL1) was blocked on antigen presenting cells and tumor cells. We also found that these NKT cells improved anti-tumor immunity through interaction with other immune cells. Our results imply that the combination of anti-PD-1/PDL1 with NKT cell-mediated immunotherapy would improve the treatment outcomes in cancer patients. These data may become the basis for future clinical trials.
|
